BTK-selective covalent kinase inhibitor

Ph. I completed in HV, in Ph. II

SBDD from reversible BTK inhibitor and opt.

J. Med. Chem., Mar. 4, 2020

Novartis, Basel, CH

Structure of BTK inhibitor Remibrutinib

Remibrutinib (Novartis oral BTK-selective covalent kinase inhibitor clinical candidate)


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: